Copy/Paste :) ATL1101 Antisense Therapeutics (ASX:ANP) announced...

Copy/Paste :)


ATL1101 Antisense Therapeutics (ASX:ANP) announced on 5th July 2011 that it had granted an Option to an
Exclusive License to develop and commercialise ATL1101 to Afandin Pty Ltd, subject to Afandin securing
suitable funding agreements for the program.
With the initial 6 month option period close to completion, Afandin has advised ANP that it has made
significant progress in attracting interest in the further development of ATL1101 and is currently in
discussions with a number of corporate and investor groups, some of which are currently undertaking due
diligence on ATL1101.
Consequently, Afandin has requested an extension to the Option to License ATL1101 and ANP has agreed
to a further 6 month period to enable Afandin to progress its discussions and funding arrangements for
ATL1101’s further development into Phase I/II clinical trials.
Dr. Anthony Filippis, Partner at Afandin said, “We continue to be excited by the prospects for ATL1101.
The recent news of Pfizer Inc adding an antisense drug to its pipeline through the acquisition of Excaliard
Pharmaceuticals Inc. reinforces the emerging commercial and clinical acceptance of antisense drugs as
treatments for a range of disease indications.”
Mark Diamond, CEO and Managing Director of Antisense Therapeutics added, “Given the reported interest
that Afandin has generated in what has been a difficult investment market over the last 6 months, we
believe that it is reasonable to allow Afandin an extension period in order to advance discussions with
parties interested in the further development of ATL1101. Afandin has experienced executives with an
excellent track record in cancer drug development and commercialisation and will be an excellent
development partner for ATL1101 should they be successful in their ongoing funding discussions.”

ATL1102
ATL1102 is an antisense inhibitor of CD49d, which is a subunit of Very Late Antigen-4, or VLA-4. Studies in animal models have demonstrated that inhibiting VLA-4 positively affects a number of inflammatory diseases, including multiple sclerosis, or MS.

We licensed ATL1102 to Antisense Therapeutics Limited in December 2001. In 2008, ATL reported Phase 2a results of ATL1102 showing significantly reduced disease activity in patients with relapsing remitting MS.


ATL1103

ATL1103 is an antisense drug that targets growth hormone receptor, or GHr, a receptor that, when inhibited, reduces the level of circulating insulin-like growth factor-1, or IGF-1, produced in the liver. IGF-1 is a hormone that contributes to various diseases including acromegaly and diabetic retinopathy. Diabetic retinopathy is a common disease of the eye and a leading cause of blindness. Abnormal growth of organs, face, hands and feet characterizes acromegaly. In preclinical studies, ATL1103 demonstrated significant reductions in IGF-1 levels in the blood. ATL is evaluating ATL1103 in a Phase 1 study in healthy volunteers.

L to R: George Werther, Bob Moses, Chris Belyea, Mark Diamond and Graham Mitchell





Robert Moses
Chairman


Robert (Bob) W Moses is the Chairman of the company’s Board of Directors and is also Chairman of the Remuneration Committee and a member of the Audit Committee. Formerly Vice President of CSL Limited, Bob draws on more than 35 years experience in the pharmaceutical/biotechnology industry. During the period 1993-2001, Bob played a central role in CSL’s development internationally. Prior to joining CSL, Bob was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company and Corporate Manager of New Business Development at ICI (now Orica). Bob also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly. He is currently non-executive Chairman TGR Biosciences Pty Ltd, Sylvan Scientific Limited and a director for the CRC for Polymers.



Dr Chris Belyea
Non-Executive Director

Chris Belyea, a non-executive director of the company, is Chairman of the Audit Committee and a member of the Remuneration Committee. Chris has a PhD in physics from the University of Melbourne and is a registered patent attorney. He became the founding CEO of Antisense Therapeutics in November 2000 and remained in this role until January 2002 (shortly after Antisense Therapeutics was listed on the Australian Stock Exchange). He worked for the Australian patent firm Griffith Hack & Co for 5 years before joining Circadian Technologies Limited as its Licensing and Projects Manager in 1996. In 1998 Dr Belyea became founding CEO and member of the board of Metabolic Pharmaceuticals Limited. He served with Metabolic as an executive until mid 2008 and now consults to companies on intellectual property and innovation practices.

Mark Diamond
Managing Director


Mark has over 20 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics in 2001 as CEO, Mark was employed in the US as Director, Product Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding's European operation based in the UK and International Business Development Manager with Faulding in Australia. Mark has a BSc from Monash University Victoria and an MBA from Macquarie University in NSW.



Dr Graham Mitchell
Non-Executive Director

Graham Mitchell is a non-executive director of the company and a member of its Remuneration Committee. He is an advisor in Innovation to the Victorian, Tasmanian & Northern Territory Governments, acts as Chief Scientist for the Department of Primary Industries and Department of Sustainability and Environment. Prof Mitchell is a non-executive director of Compumedics Limited, Avipep Pty Ltd, AgVic Services Pty Ltd, Adelaide Research & Innovation Pty Ltd and is a principal of Foursight Associates Pty Ltd. Dr Mitchell has held the position of Director of Research in the R&D Division of CSL Limited, non-executive Director of the Geoffrey Garndiner Dairy Foundation and for many years was a research scientist at the Walter & Eliza Hall Institute. Dr Mitchell is currently a non-executive director of Compumedics Limited.



Prof George Werther
Non-Executive Director

George Werther is a non-executive director of the company and a member of its Remuneration and Audit Committees. George is Director of the Department of Endocrinology and Diabetes at the Royal Children's Hospital, and the Centre for Hormone Research at the hospital's Murdoch Childrens Research Institute, where he also serves on its Commercialisation Committee. He has served on many national and international scientific committees, and peer review bodies, and is on the editorial board of two international scientific journals. He was the Chairman of the Scientific Advisory Board for Neuren Pharmaceuticals and is a member of the Scientific Advisory Board of California-based Tercica Pharmaceuticals. He was on the council of the Australasian Paediatric Endocrine Group and was a board director of the Australia MedicAlert Foundation. He is also a Professorial Fellow at the University of Melbourne.